Key facts
- It has raised $90K; the latest was Later Stage VC in Apr 2025.
- Notable investors include Tech Incubator Program for Startup, IBK Changgong, Colopl Next, Ahn-gook Pharm, K-Bio Bridge — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for RayMed (Healthcare Technology Systems)
- ·The full record, as it builds
Funding rounds
No funding rounds for RayMed (Healthcare Technology Systems) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RayMed (Healthcare Technology Systems)
Developed radiopharmaceutical treatment planning software designed to assess absorbed dose in patients undergoing radiopharmaceutical treatment. The company's platform utilizes PET-SPECT/CT images and applies a combination of innovative artificial intelligence and micro-dosimetry calculations to guide doctors in formulating treatment plans with radiopharmaceutical agents, enabling medical professionals to establish patient-tailored treatment plans on-site.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Employees
- 17
- Website
- ray-medx.com/
- Ownership
- Privately Held (backing)
RayMed (Healthcare Technology Systems) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RayMed (Healthcare Technology Systems) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RayMed (Healthcare Technology Systems) in its N-PORT filings yet. We sweep new filings monthly.